A more focused Sanofi is on the way

FV EUR83 vs. EUR86 NEUTRAL

News published on May Monday 30, 2016
Share on

Sanofi is currently working on reinforcing its strategic franchises which are set to drive growth into the next decade. The established products will progressively decline whereas the Diabetes/CV GBU will be highly dependent on Praluent. We see the trajectory as positive, believing that it could ultimately open the way to a new and compelling investment case.  That said, it is still a tad early in our view.

 

For more information, please contact marketing@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities